Is combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways required for efficacy in NRAS mutant tumors?
Our data indicates that targeting oncogenic NRAS-driven melanomas require decrease in both pERK and pAKT downstream of RAS-effectors for efficacy. This can be achieved by either targeting both BRAF and CRAF or BRAF and PIK3CA simultaneously in NRAS mutant tumor cells.
These findings suggest that in patients reporting similar experiences with SCD, coping differs by education and gender. Moreover, these differences in coping cannot be explained by clinical factors such as end organ damage and health care utilization. Sickle cell disease (SCD) presents a significant physical and psychological burden for persons with this chronic disease; however, little is known about how individuals with SCD--adult patients in particular--cope with disease-related stressors. The aim of this study was to identify and characterize factors that may influence the styles of coping among adults with SCD.